Naz Rahman
Stock Analyst at Maxim Group
(0.30)
# 4,320
Out of 5,055 analysts
35
Total ratings
20%
Success rate
-44.36%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KZIA Kazia Therapeutics | Maintains: Buy | $15 → $20 | $6.27 | +218.98% | 1 | Oct 2, 2025 | |
| AYTU Aytu BioPharma | Maintains: Buy | $9 → $7 | $2.10 | +233.33% | 2 | Sep 25, 2025 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $1.04 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $6.02 | +182.39% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $2.84 | +2,540.85% | 2 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $39.11 | +78.98% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $0.98 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $3.49 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $2.14 | +273.83% | 7 | Nov 13, 2024 | |
| PRFX PainReform | Downgrades: Hold | n/a | $0.90 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3 | $0.79 | +279.27% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $15.03 | +831.47% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $437.15 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.30 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.91 | +214.14% | 1 | Feb 25, 2022 |
Kazia Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $6.27
Upside: +218.98%
Aytu BioPharma
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $2.10
Upside: +233.33%
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.04
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $6.02
Upside: +182.39%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $2.84
Upside: +2,540.85%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $39.11
Upside: +78.98%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.98
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $3.49
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $2.14
Upside: +273.83%
PainReform
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.90
Upside: -
Jul 26, 2024
Initiates: Buy
Price Target: $3
Current: $0.79
Upside: +279.27%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $15.03
Upside: +831.47%
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $437.15
Upside: -
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.30
Upside: -
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $1.91
Upside: +214.14%